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Intravenous iron among cystic fibrosis patients There were 2 occasions whereby IV Ferinject® administra-Dear Editor,
We report our use of intravenous (IV) iron in five cystic
fibrosis (CF) patients, all of whom were chronically colonised
with Pseudomonas aeruginosa (PA) and had objective evidence
of iron deficiency not remedied by oral iron. We used IV ferric
carboxymaltose (Ferinject®), which is one of the new generation
dextran-free iron complex preparations, due to its effectiveness,
ease of dose calculation and reduced rate of hypersensitivity
reactions and anaphylactic shock [1]. In total, IV Ferinject® was
administered on 11 occasions from September to December 2011
while the patients were admitted for CF exacerbation.
IV Ferinject® produced a statistical significant improvement in:
1. haemoglobin (Hb, g/dL) — pre-IV iron median 10.2 (range
8.9–11.5); day-5 (or reading closest to day 5) post iron
median 11.1 (range 10.5–12.7); Wilcoxon signed rank test
p-value 0.004
2. mean cell volume (MCV, fl) — pre-IV iron median 77.6
(range 70.4–89.1); day-5 (or reading closest to day 5) post
iron median 79.7 (range 73.5–91.5); Wilcoxon signed rank
test p-value 0.004
However, we noticed a deterioration of CF respiratory
exacerbation among one of the patients (Patient A) in December
2011 after initial improvement with IV antibiotics, whereby the
only change in her management was administration of IV
Ferinject®. Her worsening symptoms at ‘Day 5’ were associated
with significant rise in her inflammatory markers.
We therefore retrospectively reviewed our use of IV iron
during CF exacerbation and found 2 further occasions whereby
IV iron administration was followed by subjective and
objective deterioration of CF respiratory exacerbation.
Patient A also experienced similar problems (worsening
symptoms with rise in inflammatory markers from ‘Day 5’) in
November 2011. Another patient (Patient B) achieved her best
FEV1 of 61% predicted for 2011 a day after IV Ferinject® in
December 2011. By ‘Day 5’ her symptoms worsened. By ‘Day 8’,
her FEV1 declined to 44% predicted (Table 1).
As a comparison, during admissions whereby IV Ferinject®
was not administered, Patient A's inflammatory markers (June
2011) and Patient B's FEV1 (June 2011) improved steadily during
their courses of IV antibiotics.1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2012.05.002tion was associated with subjective patients' perception of
worsening symptoms (after initial improvement with IV
antibiotics) but there were no objective evidence of
deterioration:1. Patient B— worsening symptoms from ‘Day 1’ (occasion 6)
2. Patient C— worsening symptoms from ‘Day 3’ (occasion 8)
Patient D suffered (non-respiratory related) sepsis in
October 2011 at ‘Day 6’ after her first course of IV Ferinject®,
although this was felt to be a coincidence. IV Ferinject® was
administered without problems on five other occasions (occasions
1–3, 10–11).
PA requires significant amounts of iron for aerobic and
anaerobic metabolism and has many efficient mechanisms to
acquire, traffic and scavenge iron from host proteins [2]. CF
patients (including non-PA colonised patients) have high levels
of extra-cellular iron in their respiratory tract secretions [3,4]. Iron
sequestration into the airways may contribute to iron deficiency
among CF patients [3] and prime the lungs for infection by PA
[4]. An in vitro study demonstrated that abnormal iron loss by CF
epithelial cells and iron accumulation promote PA formation of
antibiotic-resistant biofilm [4], suggesting a mechanism for the
persistence of PA among CF patients. Another in vitro study
showed that iron chelating compounds help to disrupt PA biofilm
formation [5].
Interestingly, that in vitro study also demonstrated that iron
supplementation can reverse the ability of synthetic chelators to
disrupt biofilm formation [5]. The Summary of Product
Characteristics for IV Ferinject® warned that “parenteral iron
must be used with caution in case of acute or chronic infection”.
There is currently no literature regarding the use of IV iron
among CF patients.
It should be noted that this retrospective review did not take into
account various confounding factors so the possible association
between IV iron and deterioration of CF respiratory exacerbation is
by no means a causal relationship. All five patients have severe
suppurative CF lung disease and may have deteriorated during a
course of IV antibiotics even if IV iron was not given. However,
the results do suggest that perhaps caution should be exercised
when using IV iron during concurrent CF exacerbation. It might be
safer to administer IV iron at the end of the antibiotics course,
monitor patients closely and possibly extending the antibiotics
course for about 7 days after administration of IV iron to cover for
potential clinical deterioration.by Elsevier B.V. All rights reserved.
Table 1
Intravenous iron among cystic fibrosis patients.
Occasion Day -7 Day -6 Day -5 Day -4 Day -3 Day -2 Day -1 
Day 0
IV iron 
given
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Patient
A
24yo
Female
FEV1
36%
1 * Iron 
study 
done 
Day-71 
Hb 11.8 11.0 10.9 10.8 10.7 * 10.5
MCV 74.3 75.4 74.9 75.9 76.8 * 77.5
WCC 19.3 13.1 10.2 8.5 8.3 8.3
CRP 50.5 47.6 53.1 21.9 16.1 11.1
2 * Day -1 for this occasion is Day 6 of 
previous occasion. As patient was in 
hospital long enough, we were able to give 
the complete course of IV Ferinject® in 2 
separate doses.
Hb * 10.5 10.5 11.6
MCV * 77.5 76.5 77.8
WCC 8.3 9.0 10.7
CRP 11.1 9.5 5.8
3 Iron 
study
Hb 8.7 9.2 9.9 8.9 9.5 10.5 9.2
MCV 81.7 81.8 80.7 82.5 82.6 83.0 83.8
WCC 10.4 10.4 10.9 12.2 8.9 11.8 10.7
CRP 28.0 25.5 25.6 12.1 14.2 12.3 14.1
4a Iron 
s tudy
Hb 11.6 10.7 10.2 10.3 10.6
MCV 87.2 86.8 87.5 86.7 89.1
WCC 13.2 16.0 14.2 13.5 15.9
CRP 72.5 74.7 89.8 57.4 135.1
5a Iron 
study
Hb 10.8 8.9 9.2 9.5 11.5 10.9
MCV 88.9 89.1 90.8 90.3 91.1 91.5
WCC 19.1 13.0 14.8 10.1 14.7 15.1 16.9
CRP 99.2 79.7 79.7 55.6 23.5 82.2 172.1
IV Iron 
not given
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12 Day 13 Day 14
WC C 20.6 15.8
CRP 60.0 37.0 33.0 30.6
Occasion Day -7 Day -6 Day -5 Day -4 Day -3 Day -2 Day -1 
Day 0
IV iron 
given
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Patient
B
22yo
Female
FEV1
61%
6b Iron 
study
*Day 
24
Hb 10.1 10.1 10.0 10.3 9.5 12.7
MCV 76.7 77.9 76.5 77.0 76.2 80.0
WCC 7.0 7.7 7.4 8.0 6.2 9.6
CRP 11.0 9.4 9.7 18.7
7a Iron 
study
Hb 11.5 11.6 11.5 11.7 12.2 12.0 12.7
MCV 80.5 79.9 80.9 79.6 80.5 81.5 81.6
WCC 6.2 6.3 4.7 3.6 4.7 5.3 7.2
CRP 8.3 8.6 3.7 2.0
FEV1 61% Day 844%
IV Iron 
not given
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12 Day 13 Day 14
WCC 8.4 3.7 3.8 3.7
CRP 41.5 6.7
FEV1 24% 37%
Patient
C
24yo
Male
FEV1
24%
8b Iron study
Hb 11.7 10.7 10.1 10.9 11.4 10.6 11.6
MCV 78.3 77.7 77.7 77.8 78.3 79.0 78.7
WCC 11.3 13.4 11.1 15.9 11.8 10.3 15.2
CRP 59.7 54.7 50.9 40.6 41.6 43.0 22.5
IV Iron 
not given
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12 Day 13 Day 14
WCC 8.7 8.6 11.3 11.3 9.7
CRP 53.9 39.3 41.1 40.3 32.6
Patient
D
23yo
Female
FEV1 
25%
9 Iron 
study
Hb 11.6 10.3 9.9 9.6 9.8 10.2 11.1
MCV 71.1 70.4 70.9 69.5 72.3 72.4 73.5
WCC 16.5 15.4 12.9 10.0 13.1 24.0 48.2
CRP 146.9 208.7 99.2 74.2 28.4 108.1 126.4
IV Iron 
not given
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12 Day 13 Day 14
WCC 14.3 6.5 6.3
CRP 60.5 72.5 37.4
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Occasion Day -7 Day -6 Day -5 Day -4 Day -3 Day -2 Day -1 
Day 0
IV iron 
given
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Patient
E
20yo
Male
FEV1
23%
10 Iron 
study
Hb 11.4 11.1 10.6 11.0 10.5
MCV 75.6 75.6 75.6 75.1 75.4
WCC 22.8 14.9 10.1 9.7 9.1
CRP 72.4 67.4 53.3 9.7 7.2
11 Iron 
study
Hb 11.1 10.2 11.1 11.0
MCV 81.5 77.6 78.9 79.7
WCC 17.4 11.5 9.0 8.4
CRP 147.7 63.6 19.9 6.2
IV Iron 
not given
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12 Day 13 Day 14
WCC 18.4 19.1 11.6
CRP 68.4 91.3 33.4
Table 1 (continued)
Table showing the haemoglobin (Hb, g/dL), mean cell volume (MCV, ﬂ), white cell count (WCC, x109/L) and c reactive protein (CRP, mg/L) of patients before and after administration of IV Ferinject®; with
WCC and CRP during an admission whereby IV Ferinject® was not administered as a comparison.
a Occasions whereby administration of IV Ferinject® was followed by both subjective and objective worsening of infection.
b Occasions whereby administration of IV Ferinject® was followed by subjective complaint from patients but no objective evidence of infection worsening.
562 Letter to the EditorIn summary, we demonstrated that IV iron may be useful
among CF patients with iron deficiency refractory to oral iron.
However, there is a potential risk of clinical deterioration
3–5 days after IV iron administration among CF patients
hospitalised with CF respiratory exacerbation. This potential
adverse reaction should be investigated in larger and prospective
trials. We would also be keen to learn of other CF centres'
experience in managing iron deficiency refractory to oral iron
supplement.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.jcf.2012.05.002.
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